Background
VRON-0200 is an immune-modulator, containing a checkpoint modifier targeting HBV core and pol (but not S) antigens, designed to enhance, broaden, and prolong T cell responses. The current Phase 1b study report evaluates safety, immunogenicity, and HBsAg data from chronically-HBV(CHB) infected patients(pts) that received VRON-0200 alone, and in combination with investigational antivirals, when added to ongoing NUC therapy.
Methods
CHB pts, NUC-suppressed with HBsAg <500IU/mL(Cohorts 1 and 2;C1/2), or <1,000IU/mL(Cohort 3;C3), were randomized to receive i.m. VRON-0200 prime on D1, w/wo VRON-0200 boost on D91; C3 receive VRON-0200 prime, followed by 6 mthly doses of elebsiran plus tobevibart (E+T) starting on D28, alone, or with a VRON-0200 boost on D196. Safety, virologic, and immunologic assessments were performed. HBsAg (ELISA;LLOD:0.05IU/mL), and T cell frequencies (IFNƔ ELISpot) were measured.
Results
As of December 19, 2025, 35 pts were included: 28(80%) male, 30(86%) Asian, median age:46 yrs, and median BL HBsAg,179 IU/mL(range:10–1169). In 12,073 pt safety days, 38 TRAEs were reported: 4-GR2, 34-GR1, with no treatment-related SAEs or D/Cs. In C1/2, all 27 had reached EOS(D360); at Day 360, 359 days post VRON-0200 prime dose, 23/27(85%) had sustained and/or continued HBsAg declines; 12/23(52%) had >50%declines; 4 pts had >1log10IU/mL reductions from baseline. A boost dose did not enhance responses, and declines were independent of BL HBsAg levels. IFNƔ ELISpot responses did not appear to be associated with HBsAg declines. In C3, within 7 days of first antiviral dose, rapid and profound HBsAg declines were observed (100% <2 IU/mL; 1 below LLOD) and were independent of BL HBsAg levels. At Day 196 (28 days post last E+T), 100% <1 IU/mL; 3 of 7 below LLOD.
Conclusions
In this Phase 1b study, VRON-0200 alone, or in combination, had no observed safety concerns, and was well tolerated. Despite not targeting HBsAg, a single VRON-0200 dose was able to induce broad and sustained anti-HBV immunity in the majority of pts. When combined with antivirals, rapid and profound HBsAg declines were observed in all patients. This novel approach, where anti-HBV immunity is “sparked” (i.e. primed) with VRON-0200, and then “fanned” (i.e. boosted) by HBV removal, supports the potential of VRON-0200 as a foundational backbone agent for future HBV Functional Cure regimens. VRON-0200 studies for HIV/HBV and HDV/HBV co-infection are in planning.